Perraudin Clémence, Bugnon Olivier, Pelletier-Fleury Nathalie
Centre de Recherche en Epidémiologie et Santé des Populations (CESP), Equipe 1: Economie de la Santé, Recherche sur les services de santé, UMRS 1018, France; Community Pharmacy, Department of Ambulatory Care & Community Medicine, University of Lausanne, Switzerland; Community Pharmacy Research Unit, Pharmaceutical Sciences Section, Universities of Geneva & Lausanne, Switzerland.
Community Pharmacy, Department of Ambulatory Care & Community Medicine, University of Lausanne, Switzerland; Community Pharmacy Research Unit, Pharmaceutical Sciences Section, Universities of Geneva & Lausanne, Switzerland.
Health Policy. 2016 Dec;120(12):1350-1362. doi: 10.1016/j.healthpol.2016.09.013. Epub 2016 Oct 5.
To synthesize cost-effectiveness analyses on professional pharmacy services (PPS) performed in Europe in order to contribute to current debates on their funding and reimbursement.
Systematic review in PubMed, Embase and the Centre for Reviews and Dissemination databases to identify full economic evaluation studies of PPS in community setting from 2004.
Twenty-one studies were included, conducted in the United-Kingdom (n=13), the Netherlands (n=3), Spain (n=2), Belgium (n=1), France (n=1) and Denmark (n=1). PPS to enhance medicine safety (interprofessional meetings to reduce errors, n=2) and access to medicines (minor ailment scheme, n=1) were in favour of their cost-effectiveness in the UK context, but the evidence is not sufficient. Eleven studies assessed PPS to improve treatment outcomes of individual patients-such as pharmaceutical care services, medication review, educational and coaching program, disease support service, medicines management and telephone-based advisory for improving adherence. Findings were contradictory and did not lead to strong conclusion. Screening programs for different diseases showed robust positive results (n=2) as well as smoking cessation services (n=5) and should be considered to be more widely available in accordance with national context.
The review provides arguments for the implementation of PPS aiming to improve public health through screening programs and smoking cessation services. However, further full economic evaluations are needed to support or refute the added value of other services.
综合欧洲开展的关于专业药学服务(PPS)的成本效益分析,以助力当前关于其资金投入和报销的讨论。
在PubMed、Embase和循证医学图书馆数据库中进行系统综述,以识别2004年以来社区环境中PPS的全面经济评估研究。
纳入了21项研究,分别在英国(n = 13)、荷兰(n = 3)、西班牙(n = 2)、比利时(n = 1)、法国(n = 1)和丹麦(n = 1)开展。在英国背景下,旨在提高用药安全性的PPS(跨专业会议以减少差错,n = 2)和改善药品可及性的PPS(小病诊疗计划,n = 1)有利于其成本效益,但证据并不充分。11项研究评估了旨在改善个体患者治疗结局的PPS,如药学服务、用药评估、教育与指导项目、疾病支持服务、药品管理以及基于电话的提高依从性咨询。结果相互矛盾,未得出有力结论。针对不同疾病的筛查项目显示出显著的积极结果(n = 2),戒烟服务也是如此(n = 5),应根据国家情况考虑更广泛地提供这些服务。
该综述为实施旨在通过筛查项目和戒烟服务改善公众健康的PPS提供了依据。然而,需要进一步的全面经济评估来支持或反驳其他服务的附加价值。